Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19
- PMID: 32542893
- PMCID: PMC7323399
- DOI: 10.1111/dth.13834
Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19
Conflict of interest statement
The authors declare no potential conflict of interest.
Figures


Similar articles
-
Acute generalized exanthematous pustulosis induced by hydroxychloroquine successfully treated with etretinate.J Dermatol. 2020 Feb;47(2):e53-e54. doi: 10.1111/1346-8138.15185. Epub 2019 Dec 15. J Dermatol. 2020. PMID: 31840277 No abstract available.
-
Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.Dermatol Ther. 2020 Jul;33(4):e13565. doi: 10.1111/dth.13565. Epub 2020 May 26. Dermatol Ther. 2020. PMID: 32401410 Free PMC article. No abstract available.
-
Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.J Med Case Rep. 2020 Nov 3;14(1):210. doi: 10.1186/s13256-020-02504-8. J Med Case Rep. 2020. PMID: 33138853 Free PMC article.
-
Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine.Dermatol Ther. 2018 Sep;31(5):e12660. doi: 10.1111/dth.12660. Epub 2018 Aug 28. Dermatol Ther. 2018. PMID: 30152569 Review.
-
Acute generalized exanthematous pustulosis due to terbinafine.Dermatol Ther. 2018 Jul;31(4):e12617. doi: 10.1111/dth.12617. Epub 2018 May 21. Dermatol Ther. 2018. PMID: 29786933 Review.
Cited by
-
Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.J Clin Med. 2022 Jan 13;11(2):397. doi: 10.3390/jcm11020397. J Clin Med. 2022. PMID: 35054090 Free PMC article. Review.
-
Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management.Am J Clin Dermatol. 2023 Jul;24(4):557-575. doi: 10.1007/s40257-023-00779-3. Epub 2023 May 8. Am J Clin Dermatol. 2023. PMID: 37156992 Free PMC article. Review.
-
Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.Pharmaceuticals (Basel). 2022 May 21;15(5):634. doi: 10.3390/ph15050634. Pharmaceuticals (Basel). 2022. PMID: 35631460 Free PMC article. Review.
-
Acute generalized exanthematous pustulosis due to hydroxichloroquine.Dermatol Ther. 2022 Jul;35(7):e15520. doi: 10.1111/dth.15520. Epub 2022 Apr 23. Dermatol Ther. 2022. PMID: 35434875 Free PMC article. No abstract available.
-
A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.Dermatol Ther. 2021 Jan;34(1):e14662. doi: 10.1111/dth.14662. Epub 2020 Dec 26. Dermatol Ther. 2021. PMID: 33301232 Free PMC article.
References
-
- Szatkowsk J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73:843‐848. - PubMed
-
- Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol. 2004;50:650‐651. - PubMed
-
- Castner NB, Harris JC, Motaparthi K. Cyclosporine for corticosteroid‐refractory acute generalized exanthematous pustulosis due to hydroxychloroquine. Dermatol Ther. 2018;31(5):e12660. - PubMed
-
- Pearson KC, Morrell DS, Runge SR, Jolly P. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. Cutis. 2016;97(3):212‐216. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources